Endometrial cancers harboring mutated fibroblast growth factor receptor 2 protein are successfully treated with a new small tyrosine kinase inhibitor in an orthotopic …

S Taurin, CH Yang, M Reyes, S Cho… - International Journal of …, 2018 - ijgc.bmj.com
Objectives AL3818 (anlotinib) is a receptor tyrosine kinase inhibitor targeting vascular
endothelial growth factor receptors (VEGFR1, VEGFR2/KDR, and VEGFR3), stem cell factor …
被引用次数：81 相关文章
[HTML] nih.gov

[HTML][HTML] Endometrial Cancers Harboring Mutated Fibroblast Growth Factor Receptor 2 Protein Are Successfully Treated With a New Small Tyrosine Kinase Inhibitor in …

S Taurin, CH Yang, M Reyes, S Cho… - International Journal …, 2018 - ncbi.nlm.nih.gov
Objectives AL3818 (anlotinib) is a receptor tyrosine kinase inhibitor targeting vascular
endothelial growth factor receptors (VEGFR1, VEGFR2/KDR, and VEGFR3), stem cell factor …

Endometrial Cancers Harboring Mutated Fibroblast Growth Factor Receptor 2 Protein Are Successfully Treated With a New Small Tyrosine Kinase Inhibitor in an …

S Taurin, CH Yang, M Reyes, S Cho… - International …, 2018 - search.proquest.com
Objectives AL3818 (anlotinib) is a receptor tyrosine kinase inhibitor targeting vascular
endothelial growth factor receptors (VEGFR1, VEGFR2/KDR, and VEGFR3), stem cell factor …

Endometrial Cancers Harboring Mutated Fibroblast Growth Factor Receptor 2 Protein Are Successfully Treated With a New Small Tyrosine Kinase Inhibitor in an …

S Taurin, CH Yang, M Reyes, S Cho… - … : Official Journal of the …, 2018 - europepmc.org
Objectives AL3818 (anlotinib) is a receptor tyrosine kinase inhibitor targeting vascular
endothelial growth factor receptors (VEGFR1, VEGFR2/KDR, and VEGFR3), stem cell factor …

[引用][C] Endometrial Cancers Harboring Mutated Fibroblast Growth Factor Receptor 2 Protein Are Successfully Treated With a New Small Tyrosine Kinase Inhibitor in …

S Taurin, CH Yang, M Reyes… - International …, 2017 - researchdiscovery.drexel.edu
Carboplatin and paclitaxel Endometrial cancer Mutant FGFR2 Orthotopic murine model
Tyrosine kinase inhibitor Uterine Cancer

Endometrial Cancers Harboring Mutated Fibroblast Growth Factor Receptor 2 Protein Are Successfully Treated With a New Small Tyrosine Kinase Inhibitor in an …

S Taurin, CH Yang, M Reyes, S Cho… - … : official journal of …, 2018 - pubmed.ncbi.nlm.nih.gov
Objectives AL3818 (anlotinib) is a receptor tyrosine kinase inhibitor targeting vascular
endothelial growth factor receptors (VEGFR1, VEGFR2/KDR, and VEGFR3), stem cell factor …

Endometrial Cancers Harboring Mutated Fibroblast Growth Factor Receptor 2 Protein Are Successfully Treated With a New Small Tyrosine Kinase Inhibitor in an …

S Taurin, CH Yang, M Reyes, S Cho… - … : Official Journal of the …, 2018 - europepmc.org
Objectives AL3818 (anlotinib) is a receptor tyrosine kinase inhibitor targeting vascular
endothelial growth factor receptors (VEGFR1, VEGFR2/KDR, and VEGFR3), stem cell factor …
[HTML] nih.gov

[HTML][HTML] Endometrial cancers harboring mutated fibroblast growth factor receptor-2 protein are successfully treated with a new small tyrosine kinase inhibitor in an …

S Taurin, CH Yang, M Reyes, S Cho… - … cancer: official journal …, 2018 - ncbi.nlm.nih.gov
Objectives AL3818 (anlotinib) is a receptor tyrosine kinase inhibitor targeting vascular
endothelial growth factor receptors (VEGFR1, VEGFR2/KDR and VEGFR3), stem cell factor …